You are here: Industry Insights > Mayzent

News List

NICE recommends Novartis’ Mayzent on the heels of SMC approval pharmatimes
October 16, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Mayzent for use by NHS England, only a few days after the Scottish Medicines Consortium (SMC) approved the multiple sclerosis (MS) drug.
Novartis Receives Approval for Five Products from Japanese Ministry of Health americanpharmaceuticalreview
July 10, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved five new treatment options for Japanese patients.
NICE rejects Novartis' Mayzent for secondary progressive MS pharmatimes
June 29, 2020
NICE has turned down NHS funding in preliminary guidelines for use of Novatis' Mayzent (siponimod) as a treatment for secondary progressive multiple sclerosis (SPMS) with evidence of active disease.
Novartis highlights benefits of Mayzent in MS pharmatimes
April 22, 2020
New data showing the benefits of Novartis' Mayzent (siponimod) in patients with secondary progressive multiple sclerosis (SPMS) have been published in the April supplemental issue of American Academy of Neurology.
Novartis' blockbuster-to-be Mayzent helps MS patients think faster fiercepharma
May 09, 2019
Novartis’ newly approved multiple sclerosis therapy Mayzent has already shown an ability to cut disability progression and forestall brain shrinkage in patients with the secondary progressive form of the disease (SPMS). Now, it has more data to back its c
FDA approves Novartis’ oral multiple sclerosis drug Mayzent pharmaceutical-technology
April 11, 2019
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its relapsing multiple sclerosis (RMS) drug Mayzent (siponimod)...